Tags Archive Navigation
icon
-
Media ReleaseNovartis receives European approval for Cosentyx® as first and only IL-17A inhibitor for hidradenitis suppurativa
-
StoryThe future of medicine is here
-
Media ReleaseNovartis to feature new PNH and CML scientific data from broad hematology portfolio at European Hematology Association Annual Meeting
-
Media ReleaseNovartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO
-
Media ReleaseNovartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients
-
Media ReleaseNovartis erzielt kräftige Umsatzsteigerungen, eine robuste Margenerhöhung und wichtige Innovationsmeilensteine. Erhöhung der Jahresprognose
-
Media ReleaseNovartis réalise une croissance forte de son chiffre d’affaires, une expansion robuste de sa marge, des étapes majeures de l’innovation et rehausse ses prévisions pour l’exercice 2023
-
Media ReleaseNovartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance
-
Media ReleaseNovartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis
-
Media ReleaseNovartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer
-
Media ReleaseNovartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
-
Media ReleaseNovartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 14
- › Next page